LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

Search

Organon & Co

Open

SectorHealthcare

10.67 0.09

Overview

Share price change

24h

Current

Min

10.4

Max

10.94

Key metrics

By Trading Economics

Income

-174M

-87M

Sales

81M

1.6B

P/E

Sector Avg

3.866

35.293

EPS

1

Dividend yield

8.08

Profit margin

-5.443

Employees

10,000

EBITDA

124M

449M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+32.72% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

8.08%

3.07%

Next Earnings

30 Oct 2025

Next Dividend date

11 Dec 2025

Next Ex Dividend date

11 Nov 2025

Market Stats

By TradingEconomics

Market Cap

190M

2.7B

Previous open

10.58

Previous close

10.67

News Sentiment

By Acuity

50%

50%

167 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Organon & Co Chart

Past performance is not a reliable indicator of future results.

Related News

17 Sept 2025, 23:01 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 Sept 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 Sept 2025, 21:59 UTC

Earnings

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 Sept 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 Sept 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 Sept 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 Sept 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 Sept 2025, 21:00 UTC

Earnings

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 Sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Sept 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 Sept 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 Sept 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 Sept 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 Sept 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 Sept 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 Sept 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 Sept 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 Sept 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 Sept 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 Sept 2025, 16:51 UTC

Earnings

Correct: Exor 1H Net Loss -EUR624M

17 Sept 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 Sept 2025, 16:25 UTC

Earnings

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 Sept 2025, 16:23 UTC

Earnings

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Comparison

Price change

Organon & Co Forecast

Price Target

By TipRanks

32.72% upside

12 Months Forecast

Average 13.75 USD  32.72%

High 18 USD

Low 9.5 USD

Based on 2 Wall Street analysts offering 12 month price targets forOrganon & Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

8.53 / 9.18Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

167 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat